Implicity CEO Selected to Participate in HRX 2023 Panel Discussion on AI & Remote Cardiac Monitoring
The discussion will explore how AI-powered solutions are transforming healthcare delivery and improving outcomes for patients with cardiac implantable devices.
CAMBRIDGE, Mass, Sept. 18, 2023 /PRNewswire/ -- Implicity, a leader in remote patient monitoring (RPM) and cardiac data management solutions, announced today that co-founder and CEO Arnaud Rosier, MD, PhD, has been selected to participate in a panel discussion at the upcoming HRX 2023 Digital Health Event in Seattle, WA. The discussion, AI-aided Remote Interventions - Will this Transform Healthcare Delivery & Outcomes, takes place September 22, 2023, at 2:30 pm (PDT).
As part of the discussion, Dr. Rosier intends to share insights on new international recommendations for remote monitoring of cardiovascular implantable devices (CIED) released at Heart Rhythm 2023 (HRS). The expert consensus validated the benefits of using third-party service and solution poviders, such as Implicity, to ensure the highest standard of remote monitoring and improve patient outcomes.
"We recently published groundbreaking data that demonstrated our AI-powered cardiac remote monitoring technology saves lives and significantly improves health outcomes," said Dr. Rosier, electrophysiologist, CEO, and co-founder of Implicity. "I'm eager to join experts on this panel to explore key takeaways from the research and discuss how intelligent technologies can impact our healthcare system for the better now and into the future."
Research unveiled at Heart Rhythm 2023 and led by Dr. Niraj Varma, a professor of medicine and consultant electrophysiologist at the Cleveland Clinic, found patients monitored with Implicity's alert-based platform experienced a remarkable 22% relative improvement in all-cause mortality compared to conventional RPM methods.
In addition to taking part in the panel presentation, Implicity also plans to exhibit at the HRX 2023 event (Booth #704) to showcase its latest innovations and technology advancements. The remote monitoring platform incorporates AI and machine learning to enable fast and effective analysis and reporting of patient results collected by CIEDs.
For more information or to schedule a meeting, visit: www.implicity.com.
Implicity's platform provides critical health information augmented by FDA-cleared AI algorithms, enabling healthcare providers to make more informed decisions for better patient outcomes. With access to the Health Data Hub*, one of the world's largest databases of heart disease patients, Implicity is able to develop its AI solutions based on more robust data. The company is protecting more than 94,000 patients in over 195 medical facilities across the US and Europe. To learn more, visit www.implicity.com
*Health Data Hub is a health data platform established by the French government to combine existing health patient databases and facilitate their usage for research and development purposes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/implicity-ceo-selected-to-participate-in-hrx-2023-panel-discussion-on-ai--remote-cardiac-monitoring-301929736.html
Keynote Presentation by Genesys
Making the Transition from MSP to MSSP
Solutions Showcase Session